Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02745535 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT02745535 is a Phase 2 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 77 participants.
The verdict
NCT02745535, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and efficacy of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in adults with chronic hepatitis C infection who have failed to eradicate hepatitis C despite previous combination directly acting antiviral therapy.
Interventions
- DRUG Sofosbuvir/Velpatasvir/Voxilaprevir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2016-05 |
| Est. Completion | 2018-10-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02745535
The ClinicalTrials.gov registry entry for NCT02745535 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sofosbuvir/Velpatasvir/Voxilaprevir is the first listed.
NCT02745535 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02745535 about?
NCT02745535 is a clinical study titled "Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience". This study will evaluate the safety, tolerability, and efficacy of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in adults with chronic hepatitis C infection who have failed to eradicate hepatitis C despite previous combination directly acting antiviral therapy.
What is the current status of trial NCT02745535?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2016-05. Estimated completion is 2018-10-24.
What interventions are being tested in trial NCT02745535?
The interventions under investigation include: Sofosbuvir/Velpatasvir/Voxilaprevir (DRUG).
Who is sponsoring clinical trial NCT02745535?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.